Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071874 | 0.79 | CA2 (0.42) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL2029504 | 0.75 | IMPDH2 (0.33) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL9549629 | 0.75 | CA2 (0.46) | IMPDH2IMPDH1CA2CA4 | |
| SCHEMBL7508538 | 0.75 | CA2 (0.34) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL2952712 | 0.74 | ACHE (0.40) | CA1CA2CA4CA6 | |
| SCHEMBL1820953 | 0.71 | IMPDH2 (0.32) | IMPDH2IMPDH1 | |
| SCHEMBL8563125 | 0.71 | IMPDH2 (0.49) | IMPDH2IMPDH1CA2CA4 | |
| SCHEMBL1783169 | 0.71 | HTR2A (0.46) | IMPDH2IMPDH1 | |
| SCHEMBL10405923 | 0.71 | IMPDH2 (0.33) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL85826 | 0.71 | ACHE (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055975-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11021424-B2 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-2564843-B1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECH CORP (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-2471530-B1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9447006-B2 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-1888059-B1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2564842-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564843-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2471530-A1 | Redox-active Therapeutics For Treatment Of Mitochondrial Diseases And Other Conditions And Modulation Of Energy Biomarkers | Edison Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20100222436-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-1888059-A2 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS | Edison Pharmaceuticals, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006130775-A2 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS | EDISON PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-0257503-B1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE HYDROQUINONE DERIVATIVES AND D-ALPHA-TOCOPHEROL | F. HOFFMANN-LA ROCHE AG (CH) | 1990-05-23 | — | — | EP | disclosed |
| US-4808736-A | Process for the preparation of hydroquinone derivatives and d-α-tocopherol | HOFFMANN-LAROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0257503-A1 | Process for the production of optically active hydroquinone derivatives and d-alpha-tocopherol | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
| US-20100222436-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
| US-11021424-B2 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
| US-20220055975-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.